Keran Moll

According to our database, Keran Moll authored at least 2 papers between 2020 and 2022.

Collaborative distances:

• Dijkstra number of five.
• Erdős number of four.

2022

Using structured electronic health record (EHR) data to assess claims-based algorithm performance in the Food and Drug Administration (FDA)'s Biologics Effectiveness and Safety (BEST) Initiative network.

Keran Moll, Cindy Ke Zhou, Lisa Kowarski, Shayan Hobbi, Katie Fingar, Patricia Lloyd, Patrick Saunders-Hastings, Joyce Obidi, Steven A. Anderson, Nader Alawar, Veronica Hernandez-Medina, Timothy Burrell, Jeffrey Beers, John Seeger, Kandace Amend, Elizabeth Bell, Michael Miller, Hui-Lee Wong, Azadeh Shoaibi

Proceedings of the AMIA 2022, 2022

2020

The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative: How Informatics Can Assist the Secondary Use of Electronic Health Records to Inform Regulatory Decisions.

Azadeh Shoaibi, Hui-Lee Wong, Christian Reich, Keran Moll, Tina Hernandez-Boussard

Proceedings of the AMIA 2020, 2020